Original Article
Genotyping of peroxisome proliferator-activated receptor gamma (PPAR-γ) polymorphism (Pro12Ala) in Iranian population

Fatemeh Namvaran\textsuperscript{a,b}, Parvaneh Rahimi-Moghaddam\textsuperscript{a}, Negar Azarpira\textsuperscript{a,b},

Abstract

BACKGROUND: The peroxisome proliferator-activated receptor-γ (PPAR-γ) is a nuclear hormone receptor. It is predominantly expressed in adipose tissue and as a receptor for thiazolidinediones, it has drawn attentions towards itself as a key molecule to trigger pathways involving in some diseases such as cancers, type 2 diabetes, inflammations and osteoporosis. A proline changed to alanine in codon 12 of PPAR-γ gene (Pro12Ala) has been known to be responsible for decreased risk of type 2 diabetes. The aim of the present study is to investigate the frequency of Pro12Ala polymorphism in PPAR-γ in healthy Iranian population to compare with other populations. Understanding this polymorphism may help us in better diagnosis, prevention, and therapeutic approaches toward a better management of diseases such as type 2 diabetes and osteoporosis.

METHODS: 128 healthy volunteers were enrolled in this study. To determine single nucleotide polymorphisms (SNPs), we did real time polymerase chain reaction (RT-PCR), using TaqMan allelic discrimination assays.

RESULTS: Genotype frequencies for PPAR-γ gene Pro12Ala (rs1801282) polymorphism were 0.86 for CC, 0.14 for CG, 0.00 for GG while allelic frequencies were 0.93 and 0.07 for C and G, respectively.

CONCLUSIONS: There are statistical differences between the distribution of the PPAR-γ-2 Pro12Ala polymorphism in other populations and Iranian population.

KEYWORDS: PPAR Gamma, Polymorphism, Genetic, Iran.
reduction for diabetes conferred by the Ala allele,\(^\text{12}\) and it is said that persons with the Ala\(^{12}\) allele have a reduced risk of colorectal cancer,\(^\text{13}\) prostate cancer,\(^\text{14}\) endometrial cancer,\(^\text{15}\) sporadic colorectal adenoma,\(^\text{16}\) gastric cancer,\(^\text{17}\) and adenocarcinoma and peptic ulcer disease (PUD).\(^\text{10}\)

The rare allele frequencies (Ala) has been reported to range from 2% to 18% in healthy populations,\(^\text{18}\) 5.9% to 21.6% (median: 12.7%) in Caucasians, and 1.7% to 9.3% (median: 4.5%) in Eastern Asian descent (Chinese or Japanese).\(^\text{19}\) In some studies, the rare allele frequencies are reported 12% in Caucasians, 10% in Native Americans, 8% in Samoans, 4% in Japanese, 3% in African-Americans, 2% in Nauruan people, and 1% in Chinese.\(^\text{20,21}\)

Full understanding of distribution and genotype frequency of this polymorphism might have clinical utility. In this study, we analyzed 128 healthy individuals to determine PPAR-\(^{\gamma}\) (Pro12Ala) variants and identify the frequency of alleles in Iranian population.

**Methods**

128 healthy volunteers who were selected from Blood Transfusion Organization were enrolled in this study. In addition, Ethics Committee's approval and participants' consent were obtained. They were selected according to World Health Organization protocol for blood donation including all laboratory and clinical tests with normal parameters.

Peripheral blood was used for isolation ofuffy coat (rich source of DNA) with use of Ficoll gradient (Fresenius Kabi Norge AS, Norway). DNA was extracted according to Commercial DNA extraction Kit DNP protocol (DNP Extraction Kit, Sinagen Company, Tehran, Iran). To determine single nucleotide polymorphisms (SNPs), we did real time polymerase chain reaction (RT-PCR), using TaqMan (MetaBion, Germany) allelic discrimination assays based on the procedure presented by Doney et al with some modifications.\(^\text{22}\)

The primer and probes were as:

Pro12 Forward: TCCATGCTGTATGCGTTGGTGAACCT
Pro12 Reverse: CTTTACCTTGTGATATTTTGCAGACA
Pro12 Probe (Fam labelled): TCTCCTATTGACCCGAAAGCGTATTCTT
Ala12 Probe (Fam labelled): TCTCCTATTGACGCAGAAGCGATTCCTT

PCR premix consisted of commercial premix (Takara Bio Inc, Japan) with primer and TaqMan probe. Cycling was performed in a real time thermal cycler (BioRad, USA) as:

**Stage 1 (initial denaturation):** 95ºC for 10 sec
**Stage 2 (PCR):** 95ºC for 5 sec and 60ºC for 20 sec. This stage was repeated 45 times.

One product from each genotype was sequenced with ABI sequencer Genetic Analyzer (Applied Biosystems, Foster City, CA) to confirm the results.

Sample size was calculated based on Allel C in European population (p = 92.4%) and α = 0.05 and the result was n ≥ 108. Genotype and Allel frequencies were calculated and the Hardy-Weinberg equilibrium was tested using Arlequin 313 software. The frequencies of all genotypes and alleles in our population were compared with other reports. All calculations were done by SPSS statistical package (version 15.0, SPSS) using chi-square and Fisher's exact test. P value ≤ 0.05 was considered significant.

**Results**

Allele and genotypes frequencies for PPAR-\(^{\gamma}\) (rs1801282) were deviated from Hardy-Weinberg equilibrium (HWE). HWE was used for checking the normal distribution of these genotypes in our population. Its p value was ≤ 0.05 that is not significant. It might be because

| Gene | Allelic frequencies | Genotypic Frequencies | HWE |
|------|-------------------|-----------------------|------|
| PPAR | C (Pro) 238 (92.97) | G (Ala) 18 (7.03) | CC (Pro/Pro) 110 (85.94) | CG (Pro/Ala) 18 (14.06) | GG (Ala/Ala) 0 | ≤ 0.05 |

HWE: Hardy-Weinberg equilibrium,
Table 2. A comparison of allelic and genotypic frequencies (Pro12Ala) between Iranian population and others

| Population                   | n   | C  (Pro) | G  (Ala) | CC (Pro/Pro) | CG (Pro/Ala) | GG (Ala/Ala) | P (A)   | P (G)   | HWE     | Ref |
|------------------------------|-----|----------|----------|--------------|--------------|--------------|---------|---------|---------|-----|
| Iranians (this study)        | 128 | 238 (92.97) | 18 (7.03) | 110 (85.94)  | 18 (14.06)   | 0 (0.0)      |         |         | ≤ 0.05  |     |
| Asian                        | 90  | 176 (97.8)  | 4 (2.2)   | 86 (95.6)    | 4 (4.4)      | 0 (0.0)      | 0.018   | 0.015   | 1.000   | 28  |
| Asian                        | 90  | 170 (94.4)  | 10 (5.6)  | 80 (88.9)    | 10 (11.1)    | 0 (0.0)      | 0.341   | 0.335   | -       | 28  |
| Asian                        | 88  | 166 (94.3)  | 10 (5.7)  | 78 (88.6)    | 10 (11.4)    | 0 (0.0)      | 0.363   | 0.335   | 0.752   | 28  |
| Asian                        | 48  | 90 (93.8)   | 6 (6.2)   | 42 (87.5)    | 6 (12.5)     | 0 (0.0)      | 0.504   | 0.305   | 0.752   | 28  |
| Uygurs                       | 111 | 196 (89.0)  | 25 (11.0) | 86 (77.0)    | 25 (23.0)    | 0 (0.0)      | 0.071   | 0.345   | Yes     | 32  |
| Kazaks                       | 80  | 146 (91.0)  | 14 (9.0)  | 66 (83.0)    | 14 (17.0)    | 0 (0.0)      | 0.323   | 0.295   | Yes     | 32  |
| Hans                         | 102 | 193 (95.0)  | 11 (5.0)  | 91 (90.0)    | 11 (10.0)    | 0 (0.0)      | 0.302   | 0.057   | Yes     | 32  |
| Hans                         | 180 | 346 (96.1)  | 14 (3.9)  | 166 (92.2)   | 14 (7.8)     | 0 (0.0)      | 0.062   | 0.234   | NM      | 30  |
| Korea                        | 427 | 809 (94.7)  | 45 (5.3)  | 384 (89.9)   | 41 (9.6)     | 2 (0.5)      | 0.179   | 0.323   | NM      | 29  |
| Indian                       | 241 | 424 (88.0)  | 58 (12.0) | 186 (77.2)   | 52 (21.6)    | 3 (1.2)      | 0.021   | 0.254   | Yes     | 31  |
| African-American             | 48  | 92 (95.8)   | 4 (4.2)   | 44 (91.7)    | 4 (8.3)      | 0 (0.0)      | 0.234   | 0.335   | 1.000   | 28  |
| African-American             | 46  | 88 (95.7)   | 4 (4.3)   | 42 (91.3)    | 4 (8.7)      | 0 (0.0)      | 0.263   | 0.335   | 1.000   | 28  |
| African-American             | 12  | 24 (100.0)  | 0 (0.0)   | 12 (100.0)   | 0 (0.0)      | 0 (0.0)      | 0.335   | 0.335   | NM      | 28  |
| African-American             | 1005| 1964 (98.0)| 46 (2.3)  | 959 (95.4)   | 46 (4.6)     | 0 (0.0)      | 0.00    | 0.00    | Yes     | 37  |
| European                     | 44  | 82 (93.2)   | 6 (6.8)   | 38 (86.4)    | 6 (13.6)     | 0 (0.0)      | 0.345   | 0.345   | 0.752   | 28  |
| European                     | 48  | 84 (93.8)   | 6 (6.2)   | 42 (87.5)    | 6 (12.5)     | 0 (0.0)      | 0.876   | 0.335   | 0.752   | 28  |
| European                     | 120 | 222 (92.5)  | 18 (7.5)  | 104 (86.7)   | 14 (11.7)    | 2 (1.7)      | 0.295   | 0.335   | 0.251   | 28  |
| European                     | 118 | 218 (92.4)  | 18 (7.6)  | 102 (86.4)   | 14 (11.9)    | 2 (1.7)      | 0.335   | 0.335   | NM      | 28  |
| European (Caucasian)         | 22  | 40 (90.9)   | 4 (9.1)   | 18 (81.8)    | 4 (18.2)     | 0 (0.0)      | 0.335   | 0.335   | 0.752   | 28  |
| French (Caucasian)           | 318 | 555 (87.0)  | 81 (13.0) | 246 (77.4)   | 63 (19.8)    | 9 (2.8)      | 0.008   | 0.046   | Yes     | 34  |
| Ukraine                      | 39  | 61 (72.6)   | 17 (27.4) | 24 (63.0)    | 13 (33.0)    | 2 (4.4)      | 0.00    | 0.00    | NM      | 33  |
| Greece                       | 140 | 266 (32.0)  | 14 (68.0) | 126 (90.0)   | 14 (10.0)    | 0 (0.0)      | 0.335   | 0.335   | Yes     | 35  |
| Prague Czech                 | 97  | 152 (79.0)  | 42 (21.0) | 61 (63.0)    | 30 (31.0)    | 6 (6.0)      | 0.00    | 0.00    | NM      | 36  |
| Sub-Saharan African          | 120 | 240 (100.0) | 0 (0.0)   | 120 (100.0)  | 0 (0.0)      | 0 (0.0)      | 0.00    | 0.00    | NM      | 28  |

P (A): P value of x² test between allele frequencies; P (G): P value of x² test between genotypic frequencies; HWE: Hardy Weinberg equilibrium; NM: Not mentioned
of small sample size, and also same ethnic compositions that could be disappear if random sampling would be done. Also, the accuracy of our method was confirmed by sequencing; indicating decrease of possibilities in personal and instrumental errors.

The allelic frequencies were 0.93 and 0.07 for Pro and Ala, respectively. Distributions of genotypes were 0.86 for Pro/Pro, 0.14 for Ala/Pro and 0.00 for Ala/Ala which is shown in table 1. A comparison of allelic and genotypic frequencies in Iranian population and those in others is shown in table 2.

Discussion
The first understanding of the importance of PPAR-γ in human occurred in 1995, when it was identified as the receptor for the Thiazolidinedione (TZD) insulin-sensitizing drugs. Three potent and highly PPAR-γ-selective TZDs as the first new class of insulin-sensitizing agents have been used in large-scale clinical practice to date. Understanding the relation between response to drugs such as Pioglitazone and these SNPs is necessary and may be useful in individualized treatments in clinics. Pro-to-Ala exchange would reduce transcriptional activity of PPAR, and several studies reported possible involvement of Pro12Ala polymorphism in the pathogenesis of insulin resistance, atherosclerosis, adipocyte differentiation, lipid metabolism, inflammation, and malignancy. It may be associated with decreased insulin resistance and decreased risk of type 2 diabetes.

Genotypic frequencies were 85.94% for CC, 14.06% for CG, and 0% for GG and allelic frequencies were 0.93 and 0.07 for C and G, respectively. Comparing allelic and genotypic frequencies of our data with previous reports on several ethnic groups, such as reports from Asians, Indians, African Americans, Sub-Saharan Africans, Frenchs, Ukarians, and Prague Czechs, showed significant differences.

Five reports from European-Caucasians, Greeks, three reports from Asians, three reports from African Americans, some reports from Hans, Uygurs, Koreans, and Kazaks showed no significant differences between our data and their findings.

This gene might be an important thrifty gene. The frequency of the minor alanine allele in Caucasians (0.10) was comparable to the ones previously reported in other Caucasian populations. We found significant differences in minor allele frequencies between African Americans (0.04) and American Indians (0.19) compared to Caucasians. In Asians, the frequency of the minor alanine allele differs from 0.022 to 0.062 when compared to our population (0.073); it is deviate from the findings in Asia.

It was also showed that the frequency of the minor alanine allele in Uygurs (11.0) was significantly higher than that in Hans (3.9-5.0). Also There are some controversies between different studies in Europe in minor allele frequencies.

Conclusions
Statistical differences in the distribution of the PPAR-γ-2 Pro12Ala polymorphism between various populations and Iran showed the importance of studying this SNP as well. Iran is an ethno-linguistically diverse country located on southwest Asia, with 67 million populations. It seems that Iranians are genetically different from some other populations in Asia and other continents. Our study confirms this difference regarding the PPAR-γ-2 polymorphism.

Acknowledgments
This work was financially supported by research grant from Iran University of Medical Sciences and Shiraz University of Medical Sciences. (Grant No. 85/P and P/88-116)
Authors' Contributions
FN was participated in writing the proposal and the manuscript. NA and PRM were contributed in proposal and article writing. All authors have read and approved the content of the manuscript.

References
1. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006; 58(6): 726-41.
2. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20(5): 649-88.
3. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106(4): 467-72.
4. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45(12): 1661-9.
5. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-35.
6. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma gene and peak bone mineral density variation in Chinese nuclear families. Osteoporos Int 2010; 21(5): 873-82.
7. Yue H, He JW, Zhang H, Hu WW, Hu YQ, Li M, et al. No association between polymorphisms of peroxisome [corrected] proliferator-activated receptor-gamma gene and peak bone mineral density variation in Chinese nuclear families. Osteoporos Int 2010; 21(5): 873-82.
8. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997; 241(2): 270-4.
9. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004; 4(1): 61-70.
10. Prasad KN, Saxena A, Ghoshal UC, Bhagat MR, Krishmani N. Analysis of Pro12Ala PPAR gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease. Ann Oncol 2008; 19(7): 1299-303.
11. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 1992; 6(10): 1634-41.
12. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, et al. A Pro12Ala substitution in PPAR-gamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20(3): 284-7.
13. Paltoo D, Woodson K, Taylor P, Albanes D, Virtamo J, Tangrea J. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study. Cancer Lett 2003; 191(1): 67-74.
14. Paynter RA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. No evidence of a role for PPARgamma Pro12Ala polymorphism in endometrial cancer susceptibility. Pharmacogenetics 2004; 14(12): 851-6.
15. Gong Z, Xie D, Deng Z, Bostick RM, Muga SJ, Hurley TG, et al. The PPAR[gamma] Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas. Carcinogenesis 2005; 26(3): 579-85.
16. Liao SY, Zeng ZR, Leung WK, Zhou SZ, Chen B, Sung JJ, et al. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and non-cardia gastric carcinoma in Chinese. Aliment Pharmacol Ther 2006; 23(2): 289-94.
17. Tahara T, Arisawa T, Shibata T, Nakamura M, Wang F, Maruyama N, et al. Influence of peroxisome proliferatoractivated receptor (PPAR)gamma Plol2Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese. Dig Dis Sci 2007; 52(3): 614-21.
18. Paracchini V, Pedotti P, Taioli E. Genetics of leptin and obesity: a HuGE review. Am J Epidemiol 2005; 162(2): 101-14.
19. Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 2010; 171(6): 645-55.
20. Vigouroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Lascols O, et al. Human peroxisome proliferators activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipatrophy diabetes. Diabetes 1998; 47(3): 490-2.
Polymorphism of PPAR-γ

21. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, et al. The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001; 50(4): 891-4.

22. Doney A, Fischer B, Frew D, Cummings A, Flavell DM, World M, et al. Haplotype analysis of the PPARγ Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 2002; 3: 21.

23. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliwer SA. An anti-diabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270(22): 12953-6.

24. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index, and improved insulin sensitivity. Nat Genet 1998; 20(3): 284-7.

25. Rs1801282. [cited 2011 March 6]. Available from URL: http://www.snpedia.com/index.php/Rs1801282

26. Kao WH, Coresh J, Shuldiner AR, Boerwinkle E, Bray MS, Brancati FL, et al. Pro12Ala of the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower serum insulin levels in nonobese African Americans: the Atherosclerosis Risk in Communities Study. Diabetes 2003; 52(6): 1568-72.

27. Ghoussaini M, Meyre D, Lobbens S, Charpentier G, Clément K, Charles MA, et al. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet 2005; 6: 11.

28. Kaydashev IP, Rasin AM, Shlykova OA, Gorbas' IM, Smirnova IP, Petrushov AV, et al. Frequency of the Pro12Ala-polymorphism of the gene PPARγ2 in the Ukrainian population and its possible relation to the development of the metabolic syndrome. Cytol Genet 2007; 41(5): 298-302.

29. Pintérővá D, Cerná M, Kolostová K, Novota P, Cimburová M, Romzová M, et al. The frequency of alleles of the Pro12Ala polymorphism in PPARgamma2 is different between healthy controls and patients with type 2 diabetes. Folia Biol (Praha) 2004; 50(5): 153-6.

30. Xita N, Lazaros L, Georgiou I, Tsatsoulis A. The Pro12Ala Polymorphism of the PPAR-gamma gene is not associated with the polycystic ovarian syndrome. Hormones (Athens) 2009; 8(4): 267-72.

31. Fu M, Chen H, Li X, Li J, Wu B, Cheng L, et al. Association of Pro12Ala variant in peroxisome proliferator-activated receptor-gamma2 gene with type 2 diabetes mellitus. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002; 19(3): 234-8. (Chinese).

32. Li LL, Ma XL, Ran JX, Sun XF, Xu LM, Ren J, et al. Genetic polymorphism of peroxisome proliferator-activated receptor-gamma2 Pro12Ala variant in ethnic susceptibility to diabetes in Uygur, Kazak and Han subjects. Clin Exp Pharmacol Physiol 2008; 35(2): 187-91.

33. Hwang KR, Choi YM, Kim JM, Lee GH, Kim JJ, Chae SJ, et al. Association of peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism with advanced-stage endometriosis. Am J Reprod Immunol 2010; 64(5): 333-8.

34. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPAR-gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26(1): 76-80.

35. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, et al. The peroxisome proliferator-activated receptor-γ2 Pro12Ala variant: association with type 2 diabetes and trait differences. Diabetes 2001; 50: 886-90.